title: Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).
abstract: T-prolymphocytic leukemia (T-PLL), a rare aggressive mature T-cell disorder, remains frequently resistant to conventional chemotherapy. Studies have suggested that allogeneic hematopoietic stem cell transplantation (HSCT) might possibly serve to consolidate the response to initial chemotherapy. The current report summarizes the outcome of 27 T-PLL cases identified in the registry in French Society for stem cell transplantation (SFGM-TC). Prior to HSCT, 14 patients were in complete remission (CR), 10 in partial response, three refractory, or in progression. Following HSCT, 21 patients achieved CR as best response. With a median follow-up for surviving patients of 33 (range, 6-103) months, 10 patients are still alive in continuous CR. Overall survival and progression-free survival estimates at 3 yr were 36% (95% CI: 17-54%) and 26% (95% CI: 14-45%), respectively. The relapse incidence after HSCT was 47% occurring at a median of 11.7 (range, 2-24) months. Overall cumulative incidence of transplant-related mortality was 31% at 3 yr. These results suggest that HSCT may allow long-term survival in patients with T-PLL following induction treatment; however, it is associated with a significant rate of toxicity.
authors.affiliation: CHU Hôtel Dieu, Nantes, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Guillaume
authors.forename: Yves
authors.initials: Y
authors.lastname: Beguin
authors.forename: Reza
authors.initials: R
authors.lastname: Tabrizi
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Nguyen
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Eric
authors.initials: E
authors.lastname: Deconinck
authors.forename: Rabah
authors.initials: R
authors.lastname: Redjoul
authors.forename: Jérôme
authors.initials: J
authors.lastname: Cornillon
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Guillerm
authors.forename: Nathalie
authors.initials: N
authors.lastname: Contentin
authors.forename: Anne
authors.initials: A
authors.lastname: Sirvent
authors.forename: Pascal
authors.initials: P
authors.lastname: Turlure
authors.forename: Alexandra
authors.initials: A
authors.lastname: Salmon
authors.forename: Anne
authors.initials: A
authors.lastname: Huynh
authors.forename: Sylvie
authors.initials: S
authors.lastname: François
authors.forename: Régis
authors.initials: R
authors.lastname: Peffault de Latour
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Yakoub-Agha
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D005500:Follow-Up Studies; D005602:France; D005720:Gamma Rays / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015461:Leukemia, Prolymphocytic, T-Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012042:Registries; D012074:Remission Induction; D012955:Societies, Medical; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous
keywords: T-prolymphocytic leukemia; allogeneic transplantation; chronic leukemia